24302-35-0

Usage

Uses

Used in Pharmaceutical Synthesis:
p-Piperidinophenol is used as an intermediate in the synthesis of pharmaceuticals and organic compounds. Its unique structure allows it to be a valuable building block for the development of new drug candidates, particularly in the areas of pain management, neurological disorders, and psychiatric conditions.
Used in Medical Research:
p-Piperidinophenol is used as a subject of study in medical research for its potential application in the treatment of various medical conditions. Its investigation as a potential therapeutic agent is ongoing, with the aim of understanding its effects and potential uses in the medical field.
Further research is needed to fully understand the potential uses and effects of p-piperidinophenol, as its applications in different industries and medical conditions are still being explored.

InChI:InChI=1/C11H15NO/c13-11-6-4-10(5-7-11)12-8-2-1-3-9-12/h4-7,13H,1-3,8-9H2

Upstream product

• 4096-20-2 N-phenyl piperidine 
• 110-89-4 piperidine 
• 106-41-2 4-bromo-phenol 
• 111-24-0 1,5-dibromo-pentane 
• 123-30-8 4-amino-phenol 
• 637-88-7 1,4-Cyclohexanedione 
• 36603-49-3 4-(tetrahydropyran-2'-yloxy)-1-bromobenzene 
• 2156-71-0 N-chloropiperidine 
• 4920-92-7 pivalic acid phenyl ester 
• 111-29-5 1 ,5-pentanediol 
• 63256-91-7 trifluoromethanesulfonic acid 1,5-pentanediyl ester 
• 104-92-7 1-bromo-4-methoxy-benzene 
• 5097-25-6 N-(4-methoxylphenyl)piperidine 

Downstream Products

• 119641-27-9 1,5-bis-(4-piperidino-phenoxy)-pentane 
• 1149748-55-9 C₁₆H₂₄BrNO 
• 925425-69-0 1-[3-(4-Piperidin-1-yl-phenoxy)-propyl]-4-(1-trityl-1H-imidazol-4-ylmethyl)-piperidine 

Relevant academic research and scientific papers

Piperidine and 3,3,4,4,5,5-hexafluoropiperidine as terminal groups: Syntheses and properties as new liquid crystals

A series of novel ester liquid crystals with piperidine or 3,3,4,4,5,5-hexafluoropiperidine as terminal group have been prepared in good yield. Some of the new compounds show broad mesomorphic phase range and good thermal stability. Their structures were modified by varying the terminal N-heterocycles, lateral fluorine substituent on the benzene ring, and the number of the cyclohexane ring in the molecules. The compounds 3/2-0F, 5/2-0F and 3/2-1F exhibited nematic phase (N), and 5/2-1F displayed smectic B phase. Compared with compound 3/2-1F (N), 5/2-1F has a longer n-pentyl substituent on the cyclohexane ring. Variation of the terminal N-heterocycles from piperidine to 3,3,4,4,5,5-hexafluoropiperidine causes the absence of mesomorphism behaviors.

Preparation and application of aminourea-sensitive amine oxidase inhibitor

The invention provides preparation and application of an aminourea-sensitive amine oxidase inhibitor. Specifically, the invention discloses a compound as shown in a formula I which is described in thespecification or a stereoisomer or racemate or a pharmaceutically acceptable salt thereof. The invention also discloses the capability of the compound in inhibition of aminourea-sensitive amine oxidase.

N-(2-Phenoxy)ethyl imidazo[1,2-a]pyridine-3-carboxamides containing various amine moieties: Design, synthesis and antitubercular activity

Seven 2,6-disubstituted N-(2-phenoxy)ethyl imidazo[1,2-a]pyridine-3-carboxamide series containing various amine moieties were designed and synthesized as new anti-TB agents. Many of them show excellent in vitro activity against both drug-sensitive MTB strain H37Rv and two MDR-MTB clinical isolates (MIC: 0.002–0.030 μg/mL). Compounds 2f, 5e and 5g display acceptable safety and pharmacokinetic profiles, opening a new direction for further development.

Design, synthesis and biological activity of N-(2-phenoxy)ethyl imidazo[1,2-a]pyridine-3-carboxamides as new antitubercular agents

A series of N-(2-phenoxy)ethyl imidazo[1,2-a]pyridine-3-carboxamides (IPAs), based on the structure of WZY02 discovered in our lab, were designed and synthesized as new anti-TB agents. Results reveal that many of them exhibit excellent in vitro inhibitory activity with low nanomolar MIC values against both drug-sensitive MTB strain H37Rv and drug-resistant clinical isolates. Compounds 15b and 15d display good safety and pharmacokinetic profiles, suggesting their promising potential to be lead compounds for future antitubercular drug discovery.

Practical and regioselective amination of arenes using alkyl amines

The formation of carbon–nitrogen bonds for the preparation of aromatic amines is among the top five reactions carried out globally for the production of high-value materials, ranging from from bulk chemicals to pharmaceuticals and polymers. As a result of this ubiquity and diversity, methods for their preparation impact the full spectrum of chemical syntheses in academia and industry. In general, these molecules are assembled through the stepwise introduction of a reactivity handle in place of an aromatic C–H bond (that is, a nitro group, halogen or boronic acid) and a subsequent functionalization or cross-coupling. Here we show that aromatic amines can be constructed by direct reaction of arenes and alkyl amines using photocatalysis, without the need for pre-functionalization. The process enables the easy preparation of advanced building blocks, tolerates a broad range of functionalities, and multigram scale can be achieved via a batch-to-flow protocol. The merit of this strategy as a late-stage functionalization platform has been demonstrated by the modification of several drugs, agrochemicals, peptides, chiral catalysts, polymers and organometallic complexes.

BENZOTHIOPHENE ESTROGEN RECEPTOR MODULATORS

This invention is a benzothiophene estrogen receptor modulator or its pharmaceutically acceptable salt or a pharmaceutically acceptable composition thereof to treat an estrogen-related medical disorder.

SUBSTITUTED DIHYDRO AND TETRAHYDRO OXAZOLOPYRIMIDINONES, PREPARATION AND USE THEREOF

The present invention relates to a series of substituted dihydro and tetrahydro oxazolopyrimidinones, specifically, to a series of 2-substituted-2,3-dihydro-oxazolo[3,2-a]pyrimidin-7-ones and 2-substituted-2,3,5,6-tetra-hydro-oxazolo[3,2-a]pyrimidin-7-ones of formula (I): Wherein p, n, X, Y, R1, R2, R3, R4, R5, R6, R7 and R8 are as defined herein. This invention also relates to methods of making these compounds including novel intermediates. The compounds of this invention are modulators of metabotropic glutamate receptors (mGluR), particularly, mGluR2 receptor. Therefore, the compounds of this invention are useful as pharmaceutical agents, especially in the treatment and/or prevention of a variety of central nervous system disorders (CNS), including but not limited to acute and chronic neurodegenerative conditions, psychoses, convulsions, anxiety, depression, migraine, pain, sleep disorders and emesis.

Partial structures of ketoconazole as modulators of the large conductance calcium-activated potassium channel (BKCa)

A series of partial structures of ketoconazole has been synthesized and tested for activity on the large conductance calcium-activated potassium channel (BK) in bovine smooth muscle cells. This has provided openers and blockers of the channel. The results suggest that the phenyl and phenoxy moieties are important for interaction with BK, whereas the imidazole group is unimportant. The properties of the phenoxy moiety seem to determine whether the compounds act to open or block the channel.

Reduction of CYP450 inhibition in the 4-[(1H-imidazol-4-yl)methyl] piperidine series of histamine H3 receptor antagonists

A novel series of histamine H3 receptor antagonists based on the 4-[(1H-imidazol-4-yl)methyl]piperidine template displaying low CYP2D6 and CYP3A4 inhibitory profiles has been identified. Structural features responsible for the reduction of P450 activity, a typical liability of 4-substituted imidazoles, have been established.

METHOD OF PRODUCING AMINOPHENOL COMPOUNDS

The present invention provides an industrially advantageous method of producing aminophenol compounds represented by the formula (1) by a simple and easy procedure at a high yield and a high purity. The present invention provides a method of producing an aminophenol compound represented by the formula (1): (wherein each of R1 and R2, which may be the same or different, is a hydrogen atom, a substituted or unsubstituted lower alkyl group or the like; R1 and R2, taken together with the adjacent nitrogen atom, may form a 5- or 6-membered heterocycle with or without other intervening heteroatoms; the heterocycle may be substituted by 1 to 3 substituents selected from the group consisting of a hydroxyl group, a substituted or unsubstituted lower alkyl group, a substituted or unsubstituted aryl group, a substituted or unsubstituted aryloxy group and the like; and the hydroxyl group in the formula (1) is substituted on the 2- or 4-position to the amino group on the phenyl ring), which comprises allowing a cyclohexanedione compound represented by the formula (2) to react with an amine compound represented by the formula (3) (wherein R1 and R2 are as defined above), under a neutral or basic condition.